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Due to increasing prevalence of drug-
resistant bacteria and as the number of
effective antibiotics continues to shrink,
finding new methods of combating infec-
tion has become one of the largest problems
in the medical world. There is also growing
consensus that biomedical polymers of both
natural and synthetic origin can and should
play a larger role in the development of new
therapeutic strategies to treat disease. This
special issue reports on a new development
in the war against bacterial infection:
“Drug-Free Antibacterial Hybrid
Biopolymers for Medical Applications”.
This major project has been carried out
under the EC scheme of Marie Skłodowska-
Curie Actions Innovative Training
Networks and results from the work of 15
PhD students and over 30 professionals
from different universities and industries,
all of whom have worked incredibly hard
over the last 4 years to develop this innova-
tive approach.
The aim of the project was to design
and develop a series of new materials incor-
porating combinations of synthetic and nat-
ural polymers, bioglass and bioceramics
which have been equipped with antibacteri-
al functionality or with inhibitors that can
permanently deactivate bacterial proteases.  
Biomedical polymers have already
become widely used in combination with
drugs and active principles in medical
applications, such as wound care, implants
and bio film prevention. Our challenge was
to develop new medical polymers that have
an intrinsic antibacterial functionality to
achieve clinical effectiveness in the field.
This project took on that challenge and has
successfully developed new materials that
could provide practical medical solutions
without requiring them to be paired with
drug treatments.  
When looking for ways to design new
materials, our team devised three main
strategies. These have guided the progres-
sion of our project and resulted in success-
ful development of a series of novel thera-
peutic hybrid polymers to combat bacterial-
related infection:
Developing new hybrid polymers (both
synthetic and natural) provided with
antibacterial functionality;
Designing new inorganic molecular
structures with antibacterial properties;
Building new materials which incorpo-
rate natural inhibitors that can permanently
deactivate bacteriological proteases
Each of these concepts can be used indi-
vidually or in tandem when designing mate-
rials.
I would like to take this opportunity, as
coordinator of the project “Drug-Free
Antibacterial Hybrid Biopolymers for
Medical Applications”, to firstly thank our
15 PhD students who have all worked hard
to make contribution to this project: Jeddah
Marie Vasquez, Subha Purkayastha, Lukas
Gritsch, Binh Thi Thanh Phan, Elena
Marcello, Isabel Orlando, Seray Kaya,
Mahammad Maqbool, Agata Lapa,
Alexandra Paxinou, Sheila Piarali, Faezeh
Shalchy, Loris Domenicale, Ayesha Idrees
and Patricia Varela.
I would also like to express my sincere
thanks to both our academic and industry
supervisors, without whom it would have
been impossible for this project to succeed:
Professors Ipsita Roy (Scientific
Coordinator), Gianluca Ciardelli, Valeria
Chiono, Aldo Boccaccini, Atul Bhaskar,
Wenxin Wang, Jochen Salber, Doctors
Mark Cresswell, Chris Lovell, Philip
Jackson, Ian Campbell, Iban Quintana,
Maria Joao Barros, Hongyun Tai, Ellen
Tallas.
Special thanks also go to the project
manager, Dr. Stuart Maclachlan of
Lucideon, who has made a great effort to
keep the project running smoothly and pro-
ductively. 
Finally, I would like to thank the Marie
Skłodowska-Curie Actions Innovative
Training Networks H2020-MSCA-ITN-
2014 for their financial support toward this
“Drug-Free Antibacterial Hybrid
Biopolymers for Medical Applications”
project.
Prof. Dr. Xiang Zhang
Principal Consultant at Lucideon
Royal Society Industry Fellow at the
University of Cambridge
HyMedPoly received funding from the European Union’s Horizon 2020 research and innovation 
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The Art of CommercialisingResearch
Christopher Lovell
Cambridge University
E-mail: Christopher.Lovell@lucideon.com 
Prof Lowe outlined his experience of
working with companies to commercialise
innovative bio-based technologies and the
important aspects for successful entrepre-
neurship including financing methods, their
associated risk and the personal traits of the
entrepreneur.  The key steps in business
planning and the process and cost of bring
products to various market segments from
computer apps to new drugs and airliners
were then described.Clinical Need and Issues Faced byDrug-Free AntibacterialTechnology
Jochen Salber,1,2 Ayesha Idrees,2,3
Valeria Chiono,3 Gianluca Ciardelli,3
Richard Viebahn,1 Siegfried Shah2,4
1UMC Knappschaftskrankenhaus Bochum,
Clinic of Surgery, Bochum, Germany
2Experimental Surgery, Centre for Clinical
Research, Ruhr-University, Bochum, Germany
3Department of Mechanical and Aerospace
Engineering (DIMEAS), Politecnico di Torino,
Turin, Italy
4St. Marien-Hospital, Dueren, Germany
E-mail: jochen.salber@kk-bochum.de
An increasing antimicrobial resistance
(AMR) leads to a dangerous threat to the
European public health requiring measures
across all economic and social areas. The
success of major surgery and interventional
therapies and the necessary application of
modern biomaterials-based implants and
medical devices depends on the availability
of highly potent antibiotics and/or alterna-
tives.  Different reasons led to this AMR
crisis.1 The reasons are:
1. Global misuse of antibiotics by laymen
and professionals similarly;
2. Rudimental or partially completely
missing hygiene standards in health-
care;
3. “Professionals” (e.g. MDs, nurse staff)
are the main cause, directly and indi-
rectly;
4. Senseless cost reduction or ignoring
necessary investigations by the hospital
operating company;
5. Strong increase of the application of
implants, endoprostheses and medical
devices and thus the potential danger of
foreign material-associated infections;
6. Criminal error not to continue research
and development of new antibiotics
caused by governments, health insur-
ances and pharmaceutical industry;
7. Lacking knowledge about mechanisms
of antimicrobial resistance in the con-
text of Foreign Body Reaction (FBR)-
associated colonisation, biofilm forma-
tion and infection;
8. Missing or retarded clinical implemen-
tation of alternative, complementary,
drug-free antimicrobial strategies.
Antimicrobial-modified biomaterials
will play an indispensable role in modern
medicine in form of implants, wound dress-
ings and tissue engineering approaches to
prevent particularly bacterial adhesion and
biofilm formation. The prevention of micro-
bial attachment to implant surfaces and the
inhibition of their proliferation and organi-
sation in biofilms on inner and outer sur-
faces of medical devices lead to the critical
question regarding their biocompatibility.
The awareness of requirements for testing
biocompatibility correctly, comprehensive-
ly and carefully can prevent the industry
from making common mistakes that could
slow a product time to market, the aca-
demics from giving clinicians and patients
wrong hope of contemporary help, the hos-
pital operators and clinicians from buying
and applying products only tested by inade-
quate standards and finally the patients
from harming by worse medical products
and treatments.2 We suggest hereby a more
comprehensive and advanced approach on
how modern bioactive, antimicrobial and
biofilm-preventing biomaterials should be
bio-evaluated: starting with rudimental
haemo- and cytocompatibility in vitro tests,
a panel of new biomaterials and biomaterial
surface modifications should be tested
according to the latest DIN EN ISO stan-
dards 10993-4/2017-12 and -5/2009-10
with the aim to provide a shortlist of the
panel and finally to save time and money.
Depending on the final application,
advanced in vitro bio-evaluation should fol-
low by studying the interaction between
shortlisted biomaterial candidates and pri-
mary cells. We prefer to follow then two
separate routes, one route using primary
animal cells and another applying primary
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Figure 1. A prospective route of a more reliable and valid pre-clinical bio-evaluation of novel biomaterials and medical device prototypes
– Shortening the timescale from bench-to-bedside, reducing implant failures, saving money and senseless sacrificed animal lives.
human cells with respect to the target tissue
of the final implant or medical device.
Finally, the first route serves as an in vitro
pre-test platform applying haemo-, cyto-
and immunocompatibility analyses with the
aim to reduce the number of in vivo small
and particularly large animal trials accord-
ing to the intentions of the European Union
Reference Laboratory for alternatives to
animal testing and European Centre for the
Validation of Alternative Methods (EURL
ECVAM). The second route serves as a par-
allel complementary approach to compen-
sate deceptive results based on interspecies
differences in particular regarding
immunology. Furthermore, as many other
academic and industrial research groups we
started working on co-culture, multi-culture
models and finally 3D human tissue equiv-
alents.3,4 In this context, novel approaches
like human cells-derived tissues-on-a-Chip
(hTOCs) and Organs-on-a-Chip (hOOCs)
as miniaturized in vitro human tissues and
organs5 serve as the next promising step to
investigate in vitro biocompatibility of
novel multi-functionalized biomaterials
(e.g. drug-free antimicrobial biomaterials),
drug delivery systems, implants and medi-
cal devices. Once these techniques are com-
bined with in silico analysis tools (bioinfor-
matics) we would be able to generate more
reliable and valid pre-clinical data without
sacrificing even one animal. Figure 1 shows
schematically the current and prospective
promising route of novel pre-clinical in
vitro biocompatibility evaluation.
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Introduction
Learning from Nature is an increasingly
winning strategy in the design of functional
materials and device in a wide range of final
applications.  In particular, this approach
finds its obvious exploitation in the biomed-
ical sector.  In this context, a challenging
goal is to develop novel medical polymers
that have an intrinsic antibacterial function-
ality to tackle the increasing occurrence of
microbial infections.  The biomimetic strat-
egy finds here an application in designing
building blocks that mimes part or whole
natural antibacterial materials.  To this aim,
the development of different polymers,
which mimic respectively honey and
antimicrobial peptides have been explored
in the HyMedPoly project.
Research Highlights
a. To address the inability of therapeutics
to reach the site of invasion of pathogenic
bacteria in chronic wounds leading to persis-
tent infection,  a biomimetic polyurethane-
grafted poly(ionic liquid) based patchy
anisotropic colloidal particles for topical and
intradermal wound healing applications
mimicking the behaviour of Antimicrobial
peptides (AMPs) was designed.  AMPs are
essential components of immune system
forming the first line of defence against
pathogenic bacteria.  A hydrophobic liquid
monomer was grafted from the polyurethane
backbone by redox initiated aqueous het-
erophase polymerisation.  Subsequently, the
hydrophobic anion was exchanged with a
hydrophilic one.  Chemical structure was
elucidated by NMR analysis.  Cryo-TEM
images confirmed the formation of patchy
colloidal particles consisting of the self-
organised mesophases.  The particles showed
a strong bactericidal effect.
b. A honey-like hydrogel was prepared
via thiol-ene click chemistry of hyper-
branched polyethylene glycol diacrylate
and thiolated hyaluronic acid.  The hydrogel
produced antibacterial reactive oxygen
species (ROS) in the form of hydrogen per-
oxide (H2O2), through the two components
found in honey: glucose oxidase (GO)
enzyme within HB PEGDA and glucose (G)
in HA-SH.  The hydrogel was able to pro-
duce 9.11 mmol H2O2 ROS after 24 hours
with 250 U/L GO and 25 g/L G.  This con-
centration demonstrated zone of inhibition
as a measure of antibacterial activity against
several bacterial strands.
Applications, Prototypes,
Development
The sheer inability of therapeutics to
reach the location of invasion of pathogenic
bacteria in deep tissue layers or even in
interstices of cells in tissue in case of chron-
ic wounds, leads to persistent infection.  To
tackle this problem, the research approaches
described are currently developed towards
viable routes of administration:
a. The polyurethane suspension can be
delivered topically or through an intrader-
mal application.
b. An electrospun polyurethane patch
was prepared and surface modified with
polydopamine for the immobilisation of GO
enzyme, to be used in combination with the
above-described hydrogel.
With the collaboration of the industrial
partners of the project, the ESRs are now
seeking the best route for product develop-
ment and technology qualification.
Antibacterial Natural Polymers
Ipsita Roy
Applied Biotechnology Research Group,
School of Life Sciences, College of Liberal Arts
and Sciences, University of Westminster, UK
E-mail: royi@wmin.ac.uk
Natural Polymers have the potential to
be used in a variety of medical applications
due to their excellent biocompatibility, var-
ied mechanical properties and sustainable
resourcing. These include polymers such as
alginate, gelatin, chitosan, collagen, gellan
gum, silk and chitin. In addition, there is a
distinct class of natural polymers that are
produced by controlled bacterial fermenta-
tion. These include amongst others polyhy-
droxyalkanoates (PHAs),1 bacterial cellu-
lose (BC),2 γ-polyglutamate (γ-PGA) and
alginate. The added advantage of this class
of natural polymers include the highly con-
trolled production conditions which lead to
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repeatable properties, a requirement for
most applications and more so for medical
applications. 
Research Highlights
PHAs are polymers of 3,4,5 and 6-
hydroxyalkanoic acids produced by bacte-
ria, mainly under nutrient limiting condi-
tions. These are divided in to two main
types, short chain length PHAs, with
monomer chain length, C4-C5, which are
normally hard and brittle in nature; and
medium chain length PHAs, with monomer
chain length, C6-C16, which are normally
soft and elastomeric in nature. In this work
we have modified PHAs with various natu-
ral antibacterial agents including antimicro-
bial peptides and active factors from garlic,
among others. In addition, a naturally
antibacterial class of PHAs, thio-PHAs
have also been produced.3 All of these
antibacterial polymers have been charac-
terised with respect to their antibacterial
activity against Staphylococcus aureus
ATCC 6538 and Escherichia coli ATCC
8739 following ISO22916. The biocompat-
ibility of these materials have been assessed
using C2C12, L929, and NG108, a
myoblast, fibroblast and neural cell line
respectively. These antibacterial polymers
have been used for the development of tis-
sue engineering scaffolds and medical
devices.
BC is produced by several bacteria
including Gluconacetobacter xylinus and
has an inherent hydrogel-like structure. This
particular feature enables it to incorporate
more than 90% of its weight by water, thus
providing an optimal level of moisture and
turning the material into a natural wound
dressing. Moreover, BC is highly pure as it
does not contain lignin and hemicellulose,
ensuring a great degree of biocompatibility
without needing harsh purification treat-
ments. In this work the surface of cellulose
was functionalized by wet chemistry to
introduce active groups. Antibacterial stud-
ies showed a decrease in the bacterial
growth after 24 hours of contact with the
samples. The cytotoxicity evaluation using
HaCaT cells (keratinocytes) confirmed the
cytocompatibility of both modified and
unmodified BC.
References
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Introduction
The antibacterial capability of certain
natural minerals and the elements within
them is well known and this knowledge has
previously been exploited to good effect.
The incorporation of these potent antibacte-
rial agents into inorganic-based therapeutic
materials and medical devices presents
promising new opportunities to combat the
threat of widespread antimicrobial resis-
tance (AMR) to conventional antibiotic
treatments.
Research Highlights
Three distinct approaches have been
investigated for the generation of inorganic
materials with antibacterial properties: i)
the preparation of ordered and non-ordered
mesoporous silicate bioactive glasses doped
with known therapeutically useful and
antibacterial ions; ii) the preparation of
multi-substituted hydroxyapatites doped
with ions specifically for bioactivity and
antibacterial efficacy; iii) the preparation of
phosphate-based glasses and the analogous
phosphate glass fibres doped with antibac-
terial ions.
By controlling the fundamental compo-
sition and structural properties, and by
incorporating antibacterial ions in differing
amounts into the three types of material, the
relative physicochemical properties and
antibacterial efficacy of the materials can be
modulated. The most promising materials
were characterised for their antibacterial
efficacy using different in vitro methods
against various Gram negative and Gram
positive model bacterial strains. In addition,
the cytotocompatibility of these materials
were also assessed against different model
cell lines.
Different approaches towards the pro-
duction of antibacterial composite materials
have been developed.
i) Incorporation of mesoporous bioactive
silicate glass powders into polysaccha-
ride (natural polymer) and polyurethane
(synthetic polymer) thin films has been
carried out for the production of novel
antibacterial and wound-healing dress-
ings.
ii) Electrophoretic deposition of suspen-
sions of multi-substituted hydroxyap-
atite and chitosan onto metal coupons
has been studied as a general method
for the preparation of antibacterial and
bioactive medical device coatings.
iii) The unique geometry of phosphate
glass fibres supports their use as fillers
for composite materials. A highly
absorbent cellulose-phosphate glass
fibre mesh material has been developed,
again for the purpose of creating an
antibacterial, wound-healing composite
dressing.
All prototype product materials have
been additionally tested for their antibacte-
rial efficacy and cytocompatibility.
All three material types have demon-
strated excellent antibacterial behaviour and
cytocompatibility; work will now focus on
further development and optimisation of
suitable prototype product demonstrators.
Develop functionalized biopolymers products for cosmetic,pharmaceutical, biological andmedical applications
Hongyun Tai
Blafar Ltd, NovaUCD Belfield Innovation
Park, University College Dublin, Dublin,
Ireland, 
E-mail: hongyun.tai@blafar.com
Blafar Ltd. has the expertise, knowl-
edge and technologies in polymer design,
synthesis and modification which can meet
various needs for our global customers, par-
ticularly for cosmetics, personal care, phar-
maceutical and biomedical/biological uses.
Our vision and goal are to achieve the lead-
ership position in functionalized polymers
market by developing and manufacturing
polymer products as key functional ingredi-
ents for the end use products as well as
developing formulations of the end use
products. Currently, functionalized poly-
mers provided by Blafar Ltd includes PEG
based synthetic biopolymers, and natural
biopolymers and their functionalized
derivatives such as (meth)acrylate
hyaluronic acid (HA-A), thiolated
hyaluronic acid (HA-SH), collagen and
chondroitin. Moreover, Blafar Ltd has been
actively collaborating with academic insti-
tutions to develop new functionalized
biopolymers, such as the three PhD projects
in collaboration with University of
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Westminster and with University of Polito
in HyMedPoly consortium on developing
different types of drug free antibacterial
materials, which include functionalized
Polyurethane, functionalized cellulose and
functionalized PHA using various modern
chemistry approaches. These are all bio-
compatible polymers with designed func-
tionalities to allow them to have intrinsic
antibacterial properties.
Novel Antimicrobial Technologyfor Medical Devices, from BALI,IBIZA and PRINT-AID
Sebastian A.J. Zaat
Amsterdam UMC, University of Amsterdam,
Department of Medical Microbiology,
Amsterdam Infection and Immunity Institute,
Amsterdam, The Netherlands
E-mail: s.a.zaat@amc.uva.nl
Introduction
Implant-associated infections are one of
the major causes of implant failure. The
pathogenesis of these infections involves
two major bacterial strategies to protect
themselves from antimicrobials and from
the host defence.  The implant provides the
bacteria with a surface for adherence and
biofilm formation.  Within biofilms the bac-
teria are difficult to reach for antibiotics and
host immune cells.  Moreover, because of
their low metabolic activity in the biofilm,
bacteria are up to > 100-fold less suscepti-
ble to antibiotics.  The second niche for bac-
teria is the peri-implant tissue.  The combi-
nation of the implant as a foreign body
material and the bacteria deranges function-
al antimicrobial immune responses and may
down-regulate macrophage intracellular
bactericidal mechanisms, allowing bacteria
to survive in tissue and even within
macrophages.
Research Highlights
In order to prevent and treat implant
associated infections and avoid antibiotic
resistance development, we developed
novel antimicrobial strategies.  In the BALI
(Biofilm Alliance) consortium project we
developed novel anti-biofilm agents in the
form of highly potent novel Synthetic
Antimicrobial and Antibiofilm Peptides
(SAAPs).  These SAAPs have broad spec-
trum, very rapid microbicidal activity and
anti-biofilm activity, no detectable resis-
tance development, activity in human plas-
ma, and they prevent implant –associated
infection in mouse and rabbit models, as
well as skin biofilm infection by multi drug
resistant Staphylococcus aureus (MRSA)
and Acinetobacter baumannii.1,2
In the IBIZA (Imaging of Biomaterial-
associated Infection using Zebrafish
Analysis) consortium project we developed
a novel method to eradicate intracellular
bacteria.  Often used antibiotics such as
gentamicin do not kill intracellular bacteria,
since the bacteria are residing within
phago(lyso)somes, whereas the antibiotics
are entrapped in other endosomes.  In order
to “liberate” the antibiotics as well as the
phagocytosed bacteria into the cytosol in
order to allow the antibiotics to reach the
intracellular bacteria, we developed a pho-
tosensitiser-based approach. Using this
novel technology we were able to kill intra-
cellular staphylococci in macrophages in
vitro with gentamicin, and to rescue
zebrafish embryos from lethal
Staphylococcus aureus infection.3 The way
that this technology will help prevent resis-
tance development around implants will be
discussed.
In the Horizon 2020 ITN training net-
work we aim to develop technology to pro-
duce antimicrobial medical devices by addi-
tive manufacturing (“3D-printing”), with in
vitro antimicrobial activity and in vivo effi-
cacy to prevent or treat infection.  Design of
the program and initial results will be pre-
sented.
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New Anti-Biofilm Strategies fromUnderstanding Biofilm Life CycleDynamics
Jeremy S. Webb
University of Southampton, UK, and Principal
Investigator, National Biofilms Innovation
Centre (NBIC)
E-mail: j.s.webb@soton.ac.uk.
Understanding the mechanisms of
biofilm development and dispersal is pro-
viding new ways to manage biofilms and
overcome their tolerance towards antimi-
crobial compounds.  While most of these
discoveries have been made in the context
of single-species biofilms, an additional
major outstanding challenge is to move
beyond single-species models into controls
for multispecies communities’ characteris-
tic of real-world settings or infections.  In
this presentation, I will review our research
in biofilm control, including our clinical
translation of new antibiofilm technology,
in this case to disrupt biofilms within respi-
ratory infections within Cystic Fibrosis in
human clinical trials.
As part of this presentation I will also
provide an overview of the recently award-
ed National Biofilms Innovation Centre,
funded by BBSRC, Innovate UK, plus
Industry and academic partners, and discuss
the technologies, funding and collaborative
opportunities that NBIC provides.
[page 4]                                                 [Biomedical Science and Engineering 2019; 3(s1)]
                             Abstract Book
